China’s Innovent Biologics Secures Over $300 Million Investment From Sanofi
(Reuters) – Innovent Biologics Inc said on Friday Paris-based Sanofi SA would invest HK$2.42 billion ($307.88 million) in the biopharmaceutical group to jointly develop two cancer drugs in China. The all-cash investment by Sanofi unit Sanofi Foreign Participations B.V. will be at a price of HK$42.42 per Innovent share, representing a premium of about 29%…
